Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. B. Jain Pharmaceuticals Private Limited
WARNING LETTER
•B. Jain Pharmaceuticals Private Limited•August 29, 2018

B. Jain Pharmaceuticals Private Limited – FDA Warning Letter, Aug 29, 2018

Record Details

The FDA issued a Warning Letter to B. Jain Pharmaceuticals Pvt. Ltd. following an inspection from August 13-29, 2018, identifying significant CGMP violations for finished pharmaceuticals, rendering their drug products adulterated. The firm's products, The Relief Products Ring Relief (Ear Drops and Fast Dissolving Tablets), were also deemed misbranded.

Violations included failure to maintain clean and sanitary facilities, with observations of insects in raw material storage, mold-stained ceilings, and leaking containers. The firm also failed to properly clean and maintain equipment, specifically noting a cracked and exposed water system holding tank and patched piping, with no microbial test results provided for the water system. Furthermore, the quality control unit failed to provide adequate oversight for manufacturing processes. The firm's September 19, 2018, response was deemed inadequate due to a lack of supporting documentation and failure to address the scope of deficiencies.

The misbranded status of The Relief Products Ring Relief stems from their classification as prescription drugs due to potential for harmful effects, requiring supervision by a licensed practitioner, yet their labels failed to bear the "Rx only" symbol.

The FDA recommended the firm hire a qualified CGMP consultant to audit operations and evaluate corrective actions. The firm was placed on Import Alert 66-40 on January 9, 2019. The company must respond within 15 working days detailing corrective actions and a timeline for completion,

Company
B. Jain Pharmaceuticals Private Limited
Inspection date
August 29, 2018
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Carla A. Norris (Retired-FDA Compliance Officer, CDER)
View Company Profile

ID · 6a2758e4-ac2a-4cde-ac49-3d49168a593f

Violation Codes10
21 U.S.C. 353(b)(1)21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(a)21 CFR 21021 CFR 21121 CFR 211.56(a)21 CFR 211.67(a)21 CFR 211.22(a)FD&C Act 501(a)(2)(B)21 U.S.C. 353(b)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore B. Jain Pharmaceuticals Private Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.